{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T21:53:35Z","timestamp":1781819615857,"version":"3.54.5"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","funder":[{"DOI":"10.13039\/100018133","name":"VitreoRetinal Surgery Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100018133","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To evaluate real-world differences in treatment durability, functional, and anatomic outcomes in patients who initiated or switched to aflibercept 8 mg or faricimab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Patients were categorized into four cohorts: 1) initiators of aflibercept 8 mg, 2) initiators of faricimab, 3) switchers to aflibercept 8 mg, and 4) switchers to faricimab. Switchers were further stratified as early (\u22645 prior injections) or late (&gt;5 injections). Treatment durability was assessed using the mean treatment interval, defined as the average of the three most recent injection intervals before or after the switch. Multivariate linear regression models were used to assess the independent effect of treatment strategy on durability, best-corrected visual acuity (BCVA), and central subfield thickness (CST).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 10,247 patients (12,501 eyes) with either nAMD, DME, or RVO initiated aflibercept 8 mg or faricimab. Initiators achieved greater mean treatment intervals (10 weeks) than switchers (9 weeks postswitch;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.01). Early switchers showed greater durability and CST reduction (\u221266\n                      <jats:italic toggle=\"yes\">\u00b5<\/jats:italic>\n                      m) than late switchers (\u221219\n                      <jats:italic toggle=\"yes\">\u00b5<\/jats:italic>\n                      m;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.01). Faricimab initiators had greater durability (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.01) and CST reductions (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.01) compared with other cohorts. Medicare coverage was associated with longer durability than Medicare Advantage recipients (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>In this real-world cohort, initiation of faricimab or aflibercept 8 mg was associated with greater treatment intervals and improved anatomic outcomes compared with eyes that were switched from older anti-VEGF agents. These findings support early initiation of these anti-VEGF therapies and that step-therapy delays may compromise clinical outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/iae.0000000000004813","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T22:00:23Z","timestamp":1771538423000},"page":"1231-1240","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["REAL-WORLD DURABILITY OF AFLIBERCEPT 8 MG AND FARICIMAB IN INITIATORS VERSUS SWITCHERS"],"prefix":"10.1097","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0146-8882","authenticated-orcid":false,"given":"Richard N.","family":"Sather","sequence":"first","affiliation":[{"name":"Department of Ophthalmology and Visual Neurosciences, University of Minnesota, Minneapolis, Minnesota; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trent","family":"Chiang","sequence":"additional","affiliation":[{"name":"Retina Consultants of Minnesota, Edina, Minnesota."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jade Y.","family":"Moon","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Neurosciences, University of Minnesota, Minneapolis, Minnesota; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sundeep","family":"Dev","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Neurosciences, University of Minnesota, Minneapolis, Minnesota; and"},{"name":"Retina Consultants of Minnesota, Edina, Minnesota."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Belin","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Neurosciences, University of Minnesota, Minneapolis, Minnesota; and"},{"name":"Retina Consultants of Minnesota, Edina, Minnesota."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260618","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3928\/23258160-20201223-06","article-title":"Increasing incidence and prevalence of common retinal diseases in retina practices across the United States","volume":"52","author":"Rosenblatt","year":"2021","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"R2-20260618","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","article-title":"TENAYA and LUCERNE: two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2","volume":"131","author":"Khanani","year":"2024","journal-title":"Ophthalmology"},{"key":"R3-20260618","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ophtha.2023.12.026","article-title":"Faricimab treat-and-extend for diabetic macular edema: Two-year results from the randomized phase 3 YOSEMITE and RHINE trials","volume":"131","author":"Wong","year":"2024","journal-title":"Ophthalmology"},{"key":"R4-20260618","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","article-title":"Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial","volume":"403","author":"Lanzetta","year":"2024","journal-title":"Lancet (London, England)"},{"key":"R5-20260618","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/S0140-6736(23)02577-1","article-title":"Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2\/3 trial","volume":"403","author":"Brown","year":"2024","journal-title":"Lancet"},{"key":"R6-20260618","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1038\/s41433-023-02553-5","article-title":"The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study \u2013 6 month results","volume":"37","author":"Khanani","year":"2023","journal-title":"Eye"},{"key":"R7-20260618","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.oret.2023.10.018","article-title":"Clinical outcomes of faricimab in patients with previously treated neovascular age-related macular degeneration","volume":"8","author":"Pandit","year":"2024","journal-title":"Ophthalmol Retina"},{"key":"R8-20260618","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3390\/life14020193","article-title":"Real-world data on faricimab switching in treatment-refractory neovascular age-related macular degeneration","volume":"14","author":"Ng","year":"2024","journal-title":"Life"},{"key":"R9-20260618","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.20619","article-title":"Step therapy\u2014clinical algorithms, legislation, and optimal prescribing","volume":"317","author":"Fischer","year":"2017","journal-title":"JAMA"},{"key":"R10-20260618","doi-asserted-by":"crossref","first-page":"e242446","DOI":"10.1001\/jamahealthforum.2024.2446","article-title":"Macular degeneration drug prescribing patterns after step therapy introduction in medicare advantage","volume":"5","author":"Liu","year":"2024","journal-title":"JAMA Health Forum"},{"key":"R12-20260618","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/IAE.0000000000003267","article-title":"The impact of disease activity on 5-year outcomes in patients undergoing treatment for neovascular age-related macular degeneration","volume":"42","author":"Chong Teo","year":"2022","journal-title":"Retina"},{"key":"R13-20260618","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"key":"R14-20260618","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1038\/s41433-021-01620-z","article-title":"Long-term outcomes of anti-VEGF treatment of retinal vein occlusion","volume":"36","author":"Spooner","year":"2022","journal-title":"Eye"},{"key":"R15-20260618","doi-asserted-by":"crossref","first-page":"3950","DOI":"10.3390\/jcm13133950","article-title":"Retinal vein occlusion\u2013background knowledge and foreground knowledge prospects\u2014A review","volume":"13","author":"Lendzioszek","year":"2024","journal-title":"J Clin Med"},{"key":"R16-20260618","doi-asserted-by":"crossref","first-page":"578","DOI":"10.3928\/23258160-20211018-01","article-title":"Race and socioeconomic status in Anti-VEGF treatment of diabetic macular edema","volume":"52","author":"Malhotra","year":"2021","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"R17-20260618","doi-asserted-by":"crossref","first-page":"102176","DOI":"10.1016\/j.omtn.2024.102176","article-title":"Inefficacy of anti-VEGF therapy reflected in VEGF-mediated photoreceptor degeneration","volume":"35","author":"Xu","year":"2024","journal-title":"Mol Ther - Nucleic Acids"},{"key":"R18-20260618","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.ophtha.2010.01.060","article-title":"Natural history of central retinal vein occlusion: an evidence-based systematic review","volume":"117","author":"McIntosh","year":"2010","journal-title":"Ophthalmology"},{"key":"R19-20260618","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.survophthal.2023.03.004","article-title":"Fibrosis in neovascular age-related macular degeneration: a review of definitions based on clinical imaging","volume":"68","author":"Bachmeier","year":"2023","journal-title":"Surv Ophthalmol"},{"key":"R20-20260618","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ajo.2023.12.011","article-title":"Features associated with vision in eyes with subfoveal fibrosis from neovascular age-related macular degeneration","volume":"261","author":"Teo","year":"2024","journal-title":"Am J Ophthalmol"},{"key":"R21-20260618","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.2147\/DDDT.S427416","article-title":"Faricimab: transforming the future of macular diseases treatment - a comprehensive review of clinical studies","volume":"17","author":"Panos","year":"2023","journal-title":"Drug Des Devel Ther"},{"key":"R22-20260618","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1136\/bjophthalmol-2020-317337","article-title":"Visual acuity outcomes and anti-VEGF therapy intensity in macular oedema due to retinal vein occlusion: a real-world analysis of 15 613 patient eyes","volume":"105","author":"Ciulla","year":"2021","journal-title":"Br J Ophthalmol"},{"key":"R23-20260618","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1136\/bjophthalmol-2020-315933","article-title":"Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a real-world analysis of 28 658 patient eyes","volume":"105","author":"Ciulla","year":"2021","journal-title":"Br J Ophthalmol"},{"key":"R24-20260618","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.oret.2019.05.017","article-title":"Visual acuity outcomes and anti\u2013vascular endothelial growth factor therapy intensity in neovascular age-related macular degeneration patients: a real-world analysis of 49 485 eyes","volume":"4","author":"Ciulla","year":"2020","journal-title":"Ophthalmol Retina"},{"key":"R25-20260618","doi-asserted-by":"crossref","first-page":"927","DOI":"10.3390\/ph16070927","article-title":"Visual outcomes of Anti-VEGF treatment on neovascular age-related macular degeneration: a real-world population-based cohort study","volume":"16","author":"Korva-Gurung","year":"2023","journal-title":"Pharmaceuticals"},{"key":"R26-20260618","doi-asserted-by":"crossref","first-page":"101160","DOI":"10.1016\/j.preteyeres.2022.101160","article-title":"Endpoints for clinical trials in ophthalmology","volume":"97","author":"Schmetterer","year":"2023","journal-title":"Prog Retin Eye Res"},{"key":"R27-20260618","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1377\/hlthaff.2021.00822","article-title":"Variation in use and content of prescription drug step therapy protocols, within and across health plans","volume":"40","author":"Lenahan","year":"2021","journal-title":"Health Aff (Millwood)"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004813","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T21:01:15Z","timestamp":1781816475000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004813"}},"subtitle":["A Multicenter Retrospective Analysis"],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000004813","relation":{},"ISSN":["0275-004X","1539-2864"],"issn-type":[{"value":"0275-004X","type":"print"},{"value":"1539-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}